Rexahn, TheraTarget form nano science research collaboration (PharmaBiz)

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc, a developer of innovative polymer therapeutics for the treatment of cancer, announced the formation of a joint research collaboration agreement.
(read here…)

Related items

• Rexahn to close licensing and stock purchase agreements with Teva Pharmaceutical (News-Medical-Net)
• Biomoda applauds Senator for introducing legislative bill for lung cancer screening (News-Medical-Net)
• World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center (News-Medical-Net)
• OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries (News-Medical-Net)
• Clinical data on CXA-101 to be presented at ICAAC (News-Medical-Net)

Tags: cancer, collaboration agreement, company, Inc, nano, nanotech, nanotechnology, oncology, Pharmaceuticals, pharmaceuticals inc, research collaboration, Rexahn, stage, Technology, treatment of cancer

This entry was posted on Wednesday, December 16th, 2009 at 10:50 am and is filed under Technology.